Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2022-02-14 Capital/Financing Update
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Appendix 2A - Issue of Shares 19 pages 426.2KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Vectus Biosystems Limited regarding the issuance of new shares following the conversion of convertible notes. It includes detailed information about the share issue, compliance with the Corporations Act, and an Appendix 2A form for the application for quotation of securities on the Australian Securities Exchange (ASX). The content focuses on the issuance and quotation of shares, including the conversion of convertible notes and the associated cleansing notice under section 708A(5)(e) of the Corporations Act 2001. This type of document is a formal announcement about capital changes, specifically the issuance of shares and related regulatory compliance disclosures. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about share issuance and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a simple report publication announcement, but a substantive update on capital changes.
2022-02-14 English
Becoming a substantial holder 2 pages 742.1KB
Regulatory Filings
2022-02-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 6 pages 357.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting. It includes detailed financial data such as consolidated statements of cash flows, cash flow from operating, investing, and financing activities, and financing facilities. The document covers the quarter ended 31 December 2021 and provides substantive financial data and analysis for that period. It is not merely an announcement or a certification but a comprehensive quarterly report with financial statements. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-01-30 English
Chairman & CEO Address to Shareholders 38 pages 3.1MB
AGM Information Classification · 95% confidence The document is titled as the Chairman's Address to the Annual General Meeting (AGM) held on 25 January 2022. It contains detailed commentary on the company's progress, clinical trials, financial updates related to fundraising, and commercialisation efforts. The content is typical of presentations or speeches given at an AGM, focusing on business updates, strategy, and outlook rather than detailed financial statements or regulatory disclosures. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER). The length and content suggest it is not a brief announcement or a certification. Therefore, the document fits best as AGM Information (AGM-R).
2022-01-24 English
Results of Annual General Meeting 1 page 116.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement dated 25 January 2022 from Vectus Biosystems Limited regarding the results of voting on resolutions at their Annual General Meeting (AGM). It details the voting outcomes for two resolutions: election of a director and adoption of the remuneration report. The document does not contain full financial statements or detailed reports but only the official voting results. The length is 1779 characters, which is short and consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-01-24 English
Notice of Annual General Meeting / Proxy Form 8 pages 280.4KB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Vectus Biosystems Limited, detailing the date, time, and virtual format of the meeting due to COVID-19. It includes the agenda items such as receiving the Annual Report, election of a director, and adoption of the Remuneration Report. It also contains proxy voting instructions and explanatory notes related to the AGM resolutions. The document does not contain the actual Annual Report or financial statements but refers to them and provides a link to the Annual Report on the company's website. The content is typical of an AGM Notice and related explanatory materials, which are distributed to shareholders prior to the meeting to inform them of the business to be conducted and to solicit votes. Therefore, the document fits the category of AGM Information (AGM-R).
2021-12-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.